Lupin Pharmaceuticals Inc. has recalled approximately 17,814 bottles of Cefprozil for Oral Suspension USP (250mg/5mL) because the medication is superpotent, meaning it contains more of the active drug than it should. The recall affects 50 mL, 75 mL, and 100 mL bottles manufactured in India and distributed nationwide across the United States and Puerto Rico. This antibiotic medication was sold by prescription and intended for oral use in patients. Consumers should check their prescription bottles immediately to see if their medication is part of the affected lots.
A superpotent drug contains a higher concentration of active ingredients than prescribed, which can lead to unintended side effects or toxicity. Because this is an antibiotic, receiving a higher dose than intended may increase the risk of adverse reactions and complications for patients, particularly those with sensitive health conditions.
Healthcare guidance and product refund
If you or a family member were harmed by this recalled product, you may have legal rights. Consider consulting a consumer protection attorney to understand your options for compensation.
This is general information, not legal advice. Go Backs is not a law firm and does not provide legal services.
AI-Enhanced Content: The summary, action steps, and risk assessment on this page were generated by AI from official government recall data to improve readability. This is not legal or medical advice. Always refer to the official agency sources below for authoritative information.
Sources: FDA iRES · Raw API Response
openFDA Disclaimer: This recall information is sourced from the openFDA API. Do not rely on openFDA to make decisions regarding medical care. While we make every effort to ensure that data is accurate, you should assume all results are unvalidated. Refer to the openFDA terms of service for more information.